State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Community Health Management Service Center, Longgang District Peoples Hospital of Shenzhen, Shenzhen, China.
Front Immunol. 2022 Feb 21;13:824415. doi: 10.3389/fimmu.2022.824415. eCollection 2022.
The discovery of immunodominant antigens is of great significance for the development of new especially sensitive diagnostic reagents and effective vaccines in controlling tuberculosis (TB). In the present study, we targeted the T-Cell epitope-rich fragment (nucleotide position 109-552) of Rv1566c from (MTB) and got a recombinant protein Rv1566c-444 and the full-length protein Rv1566c with expression system, then compared their performances for TB diagnosis and immunogenicity in a mouse model. The results showed that Rv1566c-444 had similar sensitivity with Rv1566c (44.44% Vs 30.56%) but lower sensitivity than ESAT-6&CFP-10&Rv3615c (44.4% Vs. 94.4%) contained in a commercial kit for distinguishing TB patients from healthy donors. In immunized BALB/c mice, Rv1566c-444 elicited stronger T-helper 1 (Th1) cellular immune response over Rv1566c with higher levels of Th1 cytokine IFN-γ and IFN-γ/IL-4 expression ratio by ELISA; more importantly, with a higher proliferation of CD4 T cells and a higher proportion of CD4 TNF-α T cells with flow cytometry. Rv1566c-444 also induced a higher level of IL-6 by ELISA and a higher proportion of Rv1566c-444-specific CD8 T cells and a lower proportion of CD8 IL-4 T cells by flow cytometry compared with the Rv1566c group. Moreover, the Rv1566c-444 group showed a high IgG secretion level and the same type of CD4+ Th cell immune response (both IgG1/IgG2a >1) as its parental protein group. Our results showed the potential of the recombinant protein Rv1566c-444 enriched with T-Cell epitopes from Rv1566c as a host T cell response measuring biomarker for TB diagnosis and support further evaluation of Rv1566c-444 as vaccine antigen against MTB challenge in animal models in the form of protein mixture or fusion protein.
免疫优势抗原的发现对于开发新的、特别敏感的诊断试剂和控制结核病(TB)的有效疫苗具有重要意义。在本研究中,我们针对来自结核分枝杆菌(MTB)的 Rv1566c 的 T 细胞表位丰富片段(核苷酸位置 109-552),得到了重组蛋白 Rv1566c-444 和全长蛋白 Rv1566c 的表达系统,然后比较了它们在小鼠模型中用于 TB 诊断和免疫原性的性能。结果表明,Rv1566c-444 与 Rv1566c 的敏感性相似(44.44% vs 30.56%),但低于商业试剂盒中包含的 ESAT-6&CFP-10&Rv3615c(44.4% vs. 94.4%)用于区分 TB 患者和健康供体。在免疫的 BALB/c 小鼠中,Rv1566c-444 比全长蛋白 Rv1566c 引起更强的 Th1 细胞免疫反应,ELISA 检测到更高水平的 Th1 细胞因子 IFN-γ 和 IFN-γ/IL-4 表达比值;更重要的是,用流式细胞术检测到 CD4 T 细胞增殖更高,CD4 TNF-α T 细胞比例更高。与 Rv1566c 组相比,Rv1566c-444 还通过 ELISA 诱导更高水平的 IL-6,通过流式细胞术检测到更高比例的 Rv1566c-444 特异性 CD8 T 细胞和更低比例的 CD8 IL-4 T 细胞。此外,Rv1566c-444 组显示出高 IgG 分泌水平和与其亲本蛋白组相同类型的 CD4+ Th 细胞免疫反应(均 IgG1/IgG2a>1)。我们的结果表明,富含 Rv1566c T 细胞表位的重组蛋白 Rv1566c-444 具有作为 TB 诊断宿主 T 细胞反应测量生物标志物的潜力,并支持进一步评估 Rv1566c-444 作为 MTB 挑战的疫苗抗原的形式在动物模型中的蛋白质混合物或融合蛋白。